Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Receivables - Other (2019 - 2023)

Historic Receivables - Other for AVITA Medical (AVHHL) over the last 5 years, with Q4 2023 value amounting to $30000.0.

  • AVITA Medical's Receivables - Other fell 9665.92% to $30000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $30000.0, marking a year-over-year decrease of 9665.92%. This contributed to the annual value of $56000.0 for FY2024, which is 8666.67% up from last year.
  • As of Q4 2023, AVITA Medical's Receivables - Other stood at $30000.0, which was down 9665.92% from $201000.0 recorded in Q3 2023.
  • Over the past 5 years, AVITA Medical's Receivables - Other peaked at $3.9 million during Q2 2021, and registered a low of $30000.0 during Q4 2023.
  • Over the past 5 years, AVITA Medical's median Receivables - Other value was $441000.0 (recorded in 2020), while the average stood at $846562.5.
  • In the last 5 years, AVITA Medical's Receivables - Other skyrocketed by 100561.8% in 2021 and then tumbled by 9665.92% in 2023.
  • Quarter analysis of 5 years shows AVITA Medical's Receivables - Other stood at $382000.0 in 2019, then grew by 15.18% to $440000.0 in 2020, then dropped by 30.0% to $308000.0 in 2021, then soared by 191.56% to $898000.0 in 2022, then plummeted by 96.66% to $30000.0 in 2023.
  • Its Receivables - Other was $30000.0 in Q4 2023, compared to $201000.0 in Q3 2023 and $442000.0 in Q2 2023.